The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.

MLA

Crouwel, Femke, et al. “The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.” Inflammatory Bowel Diseases, vol. 30, no. 9, Sept. 2024, pp. 1492–99. EBSCOhost, https://doi.org/10.1093/ibd/izad197.

APA

Crouwel, F., Bayoumy, A. B., Mulder, C. J. J., Peters, J. H. C., Boekema, P. J., Derijks, L. J. J., de Boer, S. Y., van de Meeberg, P. C., Ahmad, I., Buiter, H. J. C., & de Boer, N. K. (2024). The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 30(9), 1492–1499. https://doi.org/10.1093/ibd/izad197

Chicago

Crouwel, Femke, Ahmed B Bayoumy, Chris J J Mulder, Job H C Peters, Paul J Boekema, Luc J J Derijks, Sybrand Y de Boer, et al. 2024. “The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.” Inflammatory Bowel Diseases 30 (9): 1492–99. doi:10.1093/ibd/izad197.